Drug Approval | March 09, 2023
Eugia Pharma receives USFDA approval for Lenalidomide Capsules
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules
Shilpa Medicare Ltd's finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana has received Health Canada GMP approval
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
Plans to double its manufacturing footprint to bolster the growth
RYALTRIS is a fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular, in one easy-to-use nasal spray
_256_384.jpg){kind=logo}
Veda Corporate Advisors was the exclusive financial advisor to SHPL and its shareholders.
The approved product has an estimated market size of around US $62 million for the twelve months ending June 2022 according to IQVIA
Therapy recently approved in Canada under the brand name KORSUVA
The new subsidiary follows the recent announcement of Tetra's partnership with Cannvalate Pty Ltd for the performance of clinical trials of Tetra's drug candidates in Australia.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
